From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Call me woke, but I still like Johnson Matthey shares

By Chris Bailey | Thursday 25 May 2023


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I have been really quite pleased with my pension fund performance over the last eighteen months or so. Thanks primarily to a couple of rather good tobacco sector performers, despite me never being a smoker, last year I made some money. And this year has been absolutely fine too. Don’t worry, I am not sad enough to try to become an institutional fund manager again and it is also not as if I have not had any investment disappointments. Believe me, anyone who claims they are more than an eight out of ten investor is a liar in my opinion (and if you are regularly more than seven out of ten, then I assume you are appearing on the front page of some business newspaper or equivalent). As for this year, one of the reasons why I am not a regular seven out of ten (or more) investor is associated with Johnson Matthey (JMAT).
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:41:44